|
Market Closed -
NYSE
21:00:00 24/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 2.750 USD | -1.79% |
|
+1.85% | +52.78% |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 221.6 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 53.06% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 221.6 | 221.6 | 221.6 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 53.06% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 11.5x | 55x | 138x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.7x | -2.3x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.7x | 3.33x | 3.22x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.7x | 3.33x | 3.22x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 9.81x | 85.6x | 196x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.24 | 0.05 | 0.02 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 82.16 | 66.48 | 68.82 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 22.59 | 2.588 | 1.131 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 19.63 | 3.794 | 1.518 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.750 | 2.750 | 2.750 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 31/03/22 | 27/02/23 | 14/03/24 | 17/03/25 | 18/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 11.46x | - | - | - | 222M | |
| 33.6x | 12.18x | 24.75x | 0.59% | 1,053B | |
| 30.11x | 6.7x | 18.74x | 1.98% | 652B | |
| 33.53x | 7.84x | 16.21x | 2.59% | 468B | |
| 19.76x | 4.82x | 11.93x | 2.75% | 351B | |
| 20.25x | 5.27x | 13.08x | 3.03% | 273B | |
| 20.9x | 4.34x | 12.34x | 2.04% | 254B | |
| 25.65x | 6.7x | 11.94x | 2.48% | 220B | |
| -45.27x | 6.59x | 25.75x | 2.2% | 186B | |
| 11.33x | 4.13x | 8.58x | 4.44% | 170B | |
| Average | 16.13x | 6.51x | 15.92x | 2.46% | 362.76B | |
| Weighted average by Cap. | 24.17x | 7.86x | 18.10x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
